Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis
Authors:
Open Access
- 30 October 2015
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 15 (1) , 1-8
Abstract
Syndecan-1 plays a vital role in the suppression, transformation, and migration of several cancer types, including colorectal cancer (CRC). However, the prognostic and clinical significance of syndecan-1 in CRC remains conflicting. Therefore, we performed a meta-analysis to clarify this relationship. A comprehensive literature search for relevant studies published up to December 2014 was performed using PubMed, EMBASE, and Ovid library database. The odds ratio (OR) and pooled hazard ratio (HR) with their 95 % confidence intervals (CI) were used to estimate the effects. Ten studies with 888 CRC patients were selected for evaluation. The results showed that syndecan-1 expression was lower in CRC tissue than in normal colorectal tissue (OR = 0.02, 95 % CI = 0.00–0.09), and lower in the advanced stage than in the early stage (OR = 2.24, 95 % CI = 1.14 − 4.42). Additionally, syndecan-1 expression was higher in well and moderately differentiated CRC than in poorly differentiated CRC (OR = 2.91, 95 % CI = 1.21–6.98); no significant difference was found in patients with or without lymph node metastasis (OR = 0.91, 95 % CI = 0.34–2.43) and distant metastasis (OR = 0.89, 95 % CI = 0.19-4.21). The pooled results showed that syndecan-1 expression was not associated with survival in CRC patients (HR = 0.93, 95 % CI = 0.86–1.01). This meta-analysis indicated that loss of syndecan-1 expression is associated with CRC development, histological differentiation, and clinical stage, but not with lymph node metastasis and distant metastasis. In addition, these findings fail to support the prognostic significance of syndecan-1 in CRC.Keywords
Funding Information
- Innovation Project of Guangxi Graduate Education (YCBZ2015025)
This publication has 26 references indexed in Scilit:
- The heparanase/syndecan‐1 axis in cancer: mechanisms and therapiesThe FEBS Journal, 2013
- Syndecan‐1 modulates β‐integrin‐dependent and interleukin‐6‐dependent functions in breast cancer cell adhesion, migration, and resistance to irradiationThe FEBS Journal, 2013
- Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma CellsPLOS ONE, 2012
- Novel Processed Form of Syndecan-1 Shed from SCC-9 Cells Plays a Role in Cell MigrationPLOS ONE, 2012
- Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumorsBMC Cancer, 2008
- Syndecans in wound healing, inflammation and vascular biologyThe International Journal of Biochemistry & Cell Biology, 2007
- Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal CancerOncology, 2005
- Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal CancerJapanese Journal of Cancer Research, 2001
- Association of Syndecan-1 with Tumor Grade and Histology in Primary Invasive Cervical CarcinomaGynecologic Oncology, 1999